De novo malignant tumor after renal transplantation: single-center trial

Su Daming; Deng Wenfeng; Liu Rumin; Li Jiangtao; Fu Fangxiang; Ni Haiqiang; Hu Yangcheng; Yu Lixin; Xu Jian; Miao Yun

doi:10.3969/j.issn.1674-7445.2020.04.004

Volume 11 Issue 4

Jul. 2020

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2020 > 11(4): 449-454

Su Daming, Deng Wenfeng, Liu Rumin, et al. De novo malignant tumor after renal transplantation: single-center trial[J]. ORGAN TRANSPLANTATION, 2020, 11(4): 449-454. doi: 10.3969/j.issn.1674-7445.2020.04.004

Citation:

PDF( 1024 KB)

De novo malignant tumor after renal transplantation: single-center trial

doi: 10.3969/j.issn.1674-7445.2020.04.004

Department of Organ Transplantation, Nanfang Hospital, Nanfang Medical University, Guangzhou 510515, China

More Information

Corresponding author: Miao Yun, Email: miaoyunecho@126.com
Received Date: 2020-05-06
Available Online: 2021-01-19
Publish Date: 2020-07-15

Abstract

Abstract

Objective To analyze the incidence and risk factors of de novo malignant tumors in renal transplant recipients. Methods Clinical data of 1 549 renal transplant recipients were retrospectively analyzed, including the basic status, pathological type and incidence rate of patients with de novo malignant tumors after renal transplantation. The survival situation of these patiensts was assessed. And the risk factors of de novo malignant tumors after renal transplantation were identified. Results The incidence rate of de novo malignant tumors in renal transplant recipients was 3.03%(47/1 549). The 47 recipients were (48±12) years old when undergoing renal transplantation, and they were (55±12) years old when diagnosed malignant tumors. The time interval between transplantation and diagnosis was 66 (36, 100) months. Among the de novo malignant tumors, colorectal cancer was the most common, with a cumulative incidence rate (CIR) of 0.58%. The survival time of 47 recipients with de novo malignant tumors after renal transplantation was 59 (2, 135) months, and the 5-year survival rate was 50%. The recipients with the age > 45 years old when undergoing renal transplantation was a risk factor for de novo malignant tumors after renal transplantation (P < 0.05). Conclusions The incidence rate of de novo malignant tumors is relatively high in renal transplant recipients. The recipients with the age > 45 years old when undergoing renal transplantation is a risk factor for de novo malignant tumors.
- Renal transplantation,
- Malignant tumor,
- Cumulative incidence rate,
- Risk factor,
- Colorectal cancer,
- Survival rate

FullText(HTML)

References(25)

References

[1]	AU E, WONG G, CHAPMAN JR. Cancer in kidney transplant recipients[J]. Nat Rev Nephrol, 2018, 14(8):508-520. DOI: 10.1038/s41581-018-0022-6.
[2]	CHEUNG CY, TANG SCW. An update on cancer after kidney transplantation[J]. Nephrol Dial Transplant, 2019, 34(6):914-920. DOI: 10.1093/ndt/gfy262.
[3]	DI BARTOLOMEO S, ROLAK S, JOACHIM E, et al. Outcomes of malignant melanoma in kidney transplant recipients[J]. Clin Nephrol, 2019, 92(6):293-301. DOI: 10.5414/CN109881.
[4]	BURKE MT, ISBEL N, BARRACLOUGH KA, et al. Genetics and nonmelanoma skin cancer in kidney transplant recipients[J]. Pharmacogenomics, 2015, 16(2):161-172. DOI: 10.2217/pgs.14.156.
[5]	MATINFAR M, SHAHIDI S, FEIZI A. Incidence of nonmelanoma skin cancer in renal transplant recipients: a systematic review and Meta-analysis[J]. J Res Med Sci, 2018, 23:14. DOI: 10.4103/jrms.JRMS_817_17.
[6]	MIYAZAKI T, SATO S, KONDO T, et al. National survey of de novo malignancy after solid organ transplantation in Japan[J]. Surg Today, 2018, 48(6):618-624. DOI: 10.1007/s00595-018-1628-9.
[7]	HWANG JK, MOON IS, KIM JI. Malignancies after kidney transplantation: a 40-year single-center experience in Korea[J]. Transpl Int, 2011, 24(7):716-721. DOI: 10.1111/j.1432-2277.2011.01270.x.
[8]	LUO HL, CHIANG PH, CHENG YT, et al. Propensity-matched survival analysis of upper urinary tract urothelial carcinomas between end-stage renal disease with and without kidney transplantation[J]. Biomed Res Int, 2019:2979142. DOI: 10.1155/2019/2979142.
[9]	DING CG, LI Y, TIAN XH, et al. Predictive score model for delayed graft function based on hypothermic machine perfusion variables in kidney transplantation[J]. Chin Med J (Engl), 2018, 131(22):2651-2657. DOI: 10.4103/0366-6999.245278.
[10]	鹿宁宁, 王海燕, 张英华, 等.原发性肝癌射频消融术后针道转移再消融治疗效果分析[J].临床肝胆病杂志, 2019, 35(4):813-817. DOI: 10.3969/j.issn.1001-5256.2019.04.021. LU NN, WANG HY, ZHANG YH, et al. Clinical effect of ablation in treatment of needle tract implantation after radiofrequency ablation for primary liver cancer[J]. J Clin Hepatol, 2019, 35(4):813-817. DOI:10.3969/j.issn. 1001-5256.2019.04.021.
[11]	张健, 马麟麟, 解泽林, 等.我国肾移植术后新发恶性肿瘤总结分析[J].中华器官移植杂志, 2014, 35(12):705-710. DOI: 10.3760/cma.j.issn.0254-1785.2014.12.001. ZHANG J, MA LL, XIE ZL, et al. Analysis of malignancy following renal transplantation in China[J]. Chin J Organ Transplant, 2014, 35(12):705-710. DOI: 10.3760/cma.j.issn.0254-1785.2014.12.001.
[12]	CHEUNG CY, MA MKM, CHAU KF, et al. Posttransplant lymphoproliferative disorders in kidney transplant recipients: a retrospective cohort analysis over two decades in Hong Kong[J]. Oncotarget, 2017, 8(57):96903-96912. DOI: 10.18632/oncotarget.18890.
[13]	LI WH, CHEN YJ, TSENG WC, et al. Malignancies after renal transplantation in Taiwan: a nationwide population-based study[J]. Nephrol Dial Transplant, 2012, 27(2):833-839. DOI: 10.1093/ndt/gfr277.
[14]	KIM JH, KIM SO, HAN DJ, et al. Post-transplant malignancy: a burdensome complication in renal allograft recipients in Korea[J]. Clin Transplant, 2014, 28(4):434-442. DOI: 10.1111/ctr.12328.
[15]	HARTMANN J, SCHÜLER S, ENK AH, et al. Skin cancer in organ transplant recipients: dynamics in the incidence and clinical predictors for the first and subsequent post-transplant non-melanoma skin cancer[J]. J Eur Acad Dermatol Venereol, 2019, 33(7):1281-1289. DOI: 10.1111/jdv.15538.
[16]	SALAM A, PELEVA E, WAIN EM. Management of skin cancer in recipients of solid organ transplants[J]. Br J Hosp Med (Lond), 2019, 80(6):331-336. DOI: 10.12968/hmed.2019.80.6.331.
[17]	TSAI HI, LEE CW, KUO CF, et al. De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study[J]. Oncotarget, 2017, 8(22):36685-36695. DOI: 10.18632/oncotarget.13124.
[18]	PISELLI P, VERDIROSI D, CIMAGLIA C, et al. Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors[J]. Best Pract Res Clin Obstet Gynaecol, 2014, 28(8):1251-1265. DOI: 10.1016/j.bpobgyn.2014.08.007.
[19]	PIESIAKÓW ML, IMKO-WALCZUK B, OSIECKA K, et al. Carcinogenic viruses in etiopathogenesis of skin cancers in patients after organ transplantation[J]. Postepy Hig Med Dosw (Online), 2016, 70:86-94. DOI: 10.5604/17322693.1194807.
[20]	SIMAKACHORN L, TANPOWPONG P, LERTUDOMPHONWANIT C, et al. Various initial presentations of Epstein-Barr virus infection-associated post-transplant lymphoproliferative disorder in pediatric liver transplantation recipients: case series and literature review[J]. Pediatr Transplant, 2019, 23(2):e13357. DOI: 10.1111/petr.13357.
[21]	MERCHEA A, SHAHJEHAN F, CROOME KP, et al. Colorectal cancer characteristics and outcomes after solid organ transplantation[J]. J Oncol, 2019:5796108. DOI: 10.1155/2019/5796108.
[22]	ELSERWY NA, LOTFY EE, FOUDA MA, et al. Postrenal transplant malignancy: incidence, risk factors, and prognosis[J]. Saudi J Kidney Dis Transpl, 2017, 28(3):579-588. DOI: 10.4103/1319-2442.206456.
[23]	SPRANGERS B, NAIR V, LAUNAY-VACHER V, et al. Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network[J]. Clin Kidney J, 2018, 11(3):315-329. DOI: 10.1093/ckj/sfx122.
[24]	BAKER RJ, MARK PB, PATEL RK, et al. Renal Association clinical practice guideline in post-operative care in the kidney transplant recipient[J]. BMC Nephrol, 2017, 18(1):174. DOI: 10.1186/s12882-017-0553-2.
[25]	吴亚南, 梁颖茹, 冯志强, 等.广州市大肠癌初筛阳性人群肠镜顺应性及影响因素的随访研究[J].中山大学学报(医学科学版), 2019, 40(2):257-263. http://d.old.wanfangdata.com.cn/Periodical/zsykdxxb201902013 WU YN, LIANG YR, FENG ZQ, et al. Colonoscopy adherence and related factors among preliminary screened-positive population in Guangzhou:a follow-up study[J]. J Sun Yat-sen Univ (Med Sci), 2019, 40(2):257-263. http://d.old.wanfangdata.com.cn/Periodical/zsykdxxb201902013

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (459) PDF downloads(32)

De novo malignant tumor after renal transplantation: single-center trial

doi: 10.3969/j.issn.1674-7445.2020.04.004

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

De novo malignant tumor after renal transplantation: single-center trial

doi: 10.3969/j.issn.1674-7445.2020.04.004

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content